Gilead Updates on Phase 3 TROPiCS-04 Study Progress
Gilead Sciences announced that the Phase 3 TROPiCS-04 study of Trodelvy in metastatic urothelial cancer did not meet its primary endpoint of overall survival. While some numerical improvements were observed, there were higher deaths due to adverse events with Trodelvy. Gilead will further investigate and discuss the results with the FDA. Trodelvy remains approved for other indications, and Gilead continues to explore its use in various cancers.